Viridian Therapeutics VRDN

Drug Manufacturers - General, Healthcare

$22.37

−1.97%

Market cap: $2.5B
PE: n/m; one or more of the four quarters through 2026-06-30 missing
Forward PE: n/m; not a meaningful number
Price to sales: 35.6×
EV/EBIT: n/m; a loss over the last year
Revenue, 12 months: $71.1M; growth n/m, growth from a base too small to compare
Net margin: n/m; outside −100% to 100%
Free cash flow yield: −13.2%

Viridian Therapeutics trades at 35.6× sales. Revenue was $71.1M over the last twelve months.

Charts

Financials

Income statement for VRDN, by quarter
Income statement	Q3 FY23	Q4 FY23	Q1 FY24	Q2 FY24	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
	$72K−94%	$72K−31%	$72K−27%	$72K+0%	$86K+19%	$72K+0%	$72K+0%	$75K+4%	$70.6M+81958%	$132K+83%	$141K+96%	$284K+279%
Cost of revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gross profit	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
R&D	$30.4M+37%	$38.6M−2%	$40.9M−19%	$56.2M+40%	$69.2M+128%	$72M+87%	$76.8M+88%	$86.6M+54%	$86.3M+25%	$89.2M+24%	$77.6M+1%	$71.6M−17%
SG&A	$20.9M+136%	$33M+235%	$15M−31%	$16.1M−17%	$14.4M−31%	$15.6M−53%	$17.1M+14%	$20.2M+26%	$24.3M+69%	$33.7M+116%	$38.7M+126%	$55M+172%
	−$51.2M+72%	−$71.5M+46%	−$55.9M−23%	−$72.2M+22%	−$83.5M+63%	−$87.5M+22%	−$93.9M+68%	−$106.8M+48%	−$40M−52%	−$122.7M+40%	−$116.2M+24%	−$126.3M+18%
Interest expense	$600K+266%	$916K+445%	$587K+256%	$597K+260%	$529K−12%	$517K−44%	$550K−6%	$514K−14%	$560K+6%	$3.3M+535%	$3.5M+530%	$8.3M+1516%
Net income	−$47.7M+65%	−$66.9M+46%	−$48.5M−29%	−$65M+18%	−$76.7M+61%	−$79.7M+19%	−$86.9M+79%	−$100.7M+55%	−$34.6M−55%	−$120.4M+51%	−$104.9M+21%	−$127.1M+26%
	−$1.09+27%	−$1.34+19%	−$0.79−51%	−$1.02−20%	−$1.15+6%	n/a	−$1.07+35%	−$1.23+21%	n/a	n/a	n/a	n/a
	43.7M+29%	49.8M+23%	61.1M+45%	63.9M+48%	66.4M+52%	n/a	81.3M+33%	81.6M+28%	n/a	n/a	n/a	n/a

Revenue: Q1 FY13: 6 months less the 3 months printed beside them.

Cost of revenue: Q1 FY13: 6 months less the 3 months printed beside them.

Gross profit: Q1 FY13: 6 months less the 3 months printed beside them. 15 periods, Q2 FY13 to Q4 FY16: not printed by the filing, worked out from its own lines.

R&D: Q1 FY13: 6 months less the 3 months printed beside them.

SG&A: Q1 FY13: 6 months less the 3 months printed beside them.

Operating income: Q1 FY13: 6 months less the 3 months printed beside them.

Interest expense: Q1 FY13: 6 months less the 3 months printed beside them.

Net income: Q1 FY13: 6 months less the 3 months printed beside them.

EPS, diluted: 9 periods, Q1 FY13 to Q2 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY13: share-days: the 6-month average less the second quarter's. 9 periods, Q4 FY14 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x15).

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Viridian Therapeutics' size, closest first.

Company	Market cap	PE	Its 10y median PE	P/S	Revenue growth	Net margin
VRDNViridian Therapeutics	$2.5B	n/m	n/a	35.6×	n/m	n/m
NRIXNurix Therapeutics	$2.8B	11.0×	10.8×	3.9×	n/m	42.0%
PBHPrestige Consumer Healthcare	$2.3B	13.4×	15.3×	2.0×	−1%	15.6%
HRMYHarmony Biosciences	$2.1B	11.7×	13.8×	2.2×	+24%	18.9%
OGNOrganon	$3.6B	17.9×	5.9×	0.6×	−2%	3.4%
LQDALiquidia	$3.8B	30.7×	53.6×	8.5×	n/m	30.7%
ANIPANI Pharmaceuticals	$1.7B	15.4×	60.6×	1.7×	+31%	11.1%
ARQTArcutis Biotherapeutics	$3.9B	142×	115×	8.5×	+76%	6.1%
INDVIndivior Pharmaceuticals	$4.1B	12.4×	20.1×	3.1×	+13%	26.7%
PAHCPhibro Animal Health	$1.6B	15.9×	21.5×	1.0×	+17%	6.6%
ANABAnaptysbio	$1.5B	10.7×	100.0×	n/m	n/m	n/m
Peer median	$2.5B	14.4×	20.8×	2.2×	+17%	15.6%